LLY Stock Analysis — Eli Lilly and Company
Sector: Healthcare
AI Verdict
LLY trades at a premium the numbers actually support, but continued outperformance depends on its pipeline and the durability of its obesity drug moat.
Competitive Moat
Eli Lilly commands a defensible moat through its patent-protected diabetes and obesity drugs, notably Mounjaro and Zepbound, which have shown best-in-class efficacy and high barriers to generic competition. Its deep pipeline and strong clinical trial execution reinforce its edge in high-growth therapeutic areas.
Summary
LLY's explosive 55.1% forward EPS growth is driven by surging demand for its next-generation diabetes and obesity treatments.
Where It Stands
LLY is up 53.28% over the past year, trades at 27.3x next year's earnings (well above the healthcare sector median of 22x), and its RSI of 61.3 signals neutral-to-elevated momentum.
Key Metrics
- RSI: 61.3 — Near Overbought
- Trailing P/E: 42.3x
- Forward P/E: 27.3x
- PEG Ratio: 0.76
- Earnings Growth: +0.6%
- Revenue Growth: +0.5%
- Market Cap: $1.12T
- Dividend Yield: 0.01%
- 1-Year Return: 53.28%
- 52-Week High: $1238.00
- 52-Week Low: $623.78
Analyst Consensus
31 Buy · 7 Hold · 1 Sell (39 analysts)
Bull Case
You’re paying 27.3x forward earnings for 55.1% EPS growth, which is cheap for the growth on offer if the obesity drug franchise keeps delivering.
Bear Case
If the P/E reverts to the sector median of 22x, the stock would lose roughly 19% from here even if earnings come in as expected.
Catalyst to Watch
Watch for upcoming clinical trial readouts and FDA approvals for pipeline drugs—positive results could justify the premium multiple.